Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
Cell Therapy News
Cell Therapy News is an online resource dedicated to sharing the latest cell therapy, gene therapy, and regenerative medicine research.
Subscribe|Follow Us On
CARsgen Announces Approval of Satri-cel, the World’s First CAR T-Cell Therapy Product for Solid Tumors
[CARsgen Therapeutics] CARsgen Therapeutics announced that the New Drug Application of satricabtagene autoleucel, the autologous humanized Claudin18.2 CAR T-cell therapy product, was approved for the treatment of patients with Claudin18.2-positive, HER2-negative advanced gastric/ gastroesophageal junction adenocarcinoma who have failed at least two prior lines of therapy.
Fate Induction through Asymmetric T Cell Division Is Modulated by Chimeric Antigen Receptor Costimulatory Domains
[Nature Immunology] Researchers showed that costimulatory domains control memory fate acquisition through asymmetric cell division. CD28 CAR T cells have higher CAR surface expression and enhanced surface proteome asymmetry after the first division, yet they show muted transcriptional and metabolic divergence between daughter cells.
The Search for Safe and Effective CAR-T Targets in AML
[Blood Cancer Journal] The authors evaluated 63 acute myeloid leukemia (AML)-associated antigens for which CAR constructs have been reported. They provide a prioritized antigen landscape and a framework to guide the rational design of next-generation CARs for this challenging malignancy.
Reprogramming the Tumor Microenvironment via TFF3 Targeting: A Potential Novel Avenue to Boost CAR-T Cell Therapy in Solid Tumors
[Cancer Gene Therapy] Investigators explored how trefoil factor family (TFF) 3 signaling contributes to tumor progression and immune escape, and how its inhibition might reshape the tumor microenvironment to better support CAR-T cell activity.
Boosting CAR T Cell Functionality with Oncolytic Viruses for the Treatment of Pediatric Diffuse Midline Gliomas
[Molecular Therapy Oncology] Scientists investigated the potential of combining two oncolytic viruses, the human adenovirus B Goravir17, and type 3 mammalian orthoreovirus R12418 with CAR T cells targeting the two most promising diffuse midline gliomas targets, B7H3 and GD2.
Ultrasound Priming Gated by Solid Tumor Hallmarks to Guide CAR-T Therapy
[Science Advances] Researchers developed solid-tumor hallmark inducible, focused-ultrasound triggered enhanced reprogramming system (SHIFTERS), a platform designed to enable targeted and durable expression of clinically validated antigens in solid tumors,
Iron-Mediated Ferroptosis Impairs CAR-T Cell Function and Antitumor Efficacy
[Nature Cancer] Scientists showed that rapid expansion of CAR-T cells after infusion is followed by a ‘diminution’ phase characterized by ferroptosis-associated features and elevated serum iron levels. In preclinical cancer models in female mice and ex vivo culture systems, excess intracellular iron impaired CAR-T cell function.
Targeting TMED4 Enhances CD8 T Cell Function and CAR T Cell Efficacy in Solid Tumors through the IRE1α-Autophagy Axis
[Science Advances] The authors identified transmembrane emp24 domain-containing (TMED) as a key regulator of CD8+ T cell exhaustion and antitumor immunity. They showed that TMED4 deletion enhances the function of both CD8+ T cells and CAR T cells, improving their ability to resist exhaustion and eliminate tumors.
In Situ Reprogramming of CAR-Alveolar Macrophages via Liposomal Nanomedicine for Lung Cancer Immunotherapy
[Nature Communications] Researchers described a precision-engineered, cascade-targeted liposomal nanomedicine that enables in situ reprogramming of alveolar macrophages (AM) via a multi-step targeting strategy to generate functionally optimized chimeric antigen receptor-expressing AMs.
Dual Epitope Anti-LILRB4 Synthetic T Cell Receptor and Antigen Receptor (STAR)-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia
[Signal Transduction and Targeted Therapy] Researchers developed a synthetic T cell receptor and antigen receptor-T (STAR-T) cell therapy targeting leukocyte immunoglobulin-like receptor B4 (LILRB4), an immunosuppressive receptor highly expressed on monocytic acute myeloid leukemia blasts but not on hematopoietic stem cells.
Hallmarks and Correlates of Effective Adoptive Cell Immunotherapy for Cancer
[Nature Reviews Immunology] Scientists highlight emerging correlates of response to adoptive cell transfer and novel strategies that integrate tumor immunology, cancer genomics, computational biology, and T cell engineering for the development of next-generation cellular immunotherapies.
Antigen-Boosted CD4CAR T Cells Fail to Expand or Control Viremia in Multiple Nonhuman Primate Models of HIV
[Blood] Investigators tested a broad array of strategies to enhance CD4CAR T-cell efficacy, including CRISPR-Cas9-mediated gene editing of immune checkpoint and HIV-associated genes, single and pooled competitive infusions of engineered CAR T cells, distinct CAR constructs incorporating either CD28 or 4-1BB costimulatory domains, and exogenous antigen boosting.
Published since 2002, Cell Therapy News is our longest running online publication. Our editorial team curates the top publications, reviews, and news on in vivo gene therapy, cell therapy, and immunotherapy research. With over 15,000 subscribers and followers across our website, email newsletter, and Twitter feed, we are proud to facilitate the communication of cutting-edge cell therapy innovations.
